Clinical Report: Intensive vs Standard Statin Treatment in Acute Ischemic Stroke

Overview

This study evaluates the impact of intensive atorvastatin therapy on the risk of post-stroke pneumonia and multidrug-resistant infections in acute ischemic stroke patients.

Background

Acute ischemic stroke is a leading cause of mortality and is often complicated by post-stroke pneumonia (PSP), which can worsen patient outcomes. Statins are commonly used in stroke management for their lipid-lowering and pleiotropic effects, yet their relationship with PSP remains debated. Understanding the safety profile of intensive statin therapy is crucial for optimizing treatment strategies in stroke patients.

Data Highlights

Key Findings

• No significant difference in PSP incidence between intensive (8.8%) and standard (8.3%) atorvastatin groups (p = 0.691).
• Multivariate regression showed no increased risk of PSP with intensive treatment (OR = 1.002, 95% CI: 0.672–1.492).
• Similar proportions of severe pneumonia were observed: 21.4% in intensive vs. 20.2% in standard group (p = 0.863).
• MDR bacterial infection rates were comparable: 9.5% in intensive vs. 10.1% in standard group (p = 0.897).
• Intensive atorvastatin therapy did not elevate the risk of pneumonia or MDR infections in the acute phase of ischemic stroke.

Clinical Implications

The findings indicate that high-intensity atorvastatin therapy does not increase the risk of post-stroke pneumonia or multidrug-resistant infections.

Conclusion

Intensive atorvastatin therapy during acute ischemic stroke does not increase the risk or severity of pneumonia or multidrug-resistant infections.

Related Resources & Content

1. AHA/ASA Stroke Secondary Prevention Guideline: Key Points - American College of Cardiology, 2021
2. Atorvastatin in stroke: a review of SPARCL and subgroup analysis - PubMed, 2021
3. European Journal of Preventive Cardiology — Intake of high-intensity statin after acute myocardial infarction assessed by direct drug concentration measurement: association with LDL-C response and coronary plaque modifications in the PACMAN-AMI trial
4. Drug Safety — Influence of Pharmacogenetics and Drug-Gene Interactions on Pulmonary Toxicity Linked to Simvastatin
5. European Journal of Preventive Cardiology — One-year treatment trajectories of patients with statin intolerance: results from a multicentre registry
6. European Journal of Preventive Cardiology — High adherence to high-intensity statins after acute myocardial infarction: the ‘PACMAN pathway’
7. AHA/ASA Stroke Secondary Prevention Guideline: Key Points - American College of Cardiology
8. Atorvastatin in stroke: a review of SPARCL and subgroup analysis - PubMed
9. Understanding definitive and probable stroke-associated pneumonia: Risk factors and clinical outcomes - ScienceDirect